<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="354">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156541</url>
  </required_header>
  <id_info>
    <org_study_id>ING-HPV-1</org_study_id>
    <nct_id>NCT05156541</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts</brief_title>
  <acronym>ING-HPV-1</acronym>
  <official_title>Open Controlled Randomized Study of the Efficacy and Safety of Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts (Phase III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SPP Pharmaclon Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SPP Pharmaclon Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the effectiveness of destructive therapy for&#xD;
      anogenital warts in combination with the use of Ingaron in comparison with destructive&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Literature data and the results of preclinical studies of interferon-gamma, as well as the&#xD;
      features of HPV immunopathogenesis, show the expediency of studying the use of Ingaron in&#xD;
      this pathology.&#xD;
&#xD;
      The study was planned to include 50 outpatients of both sexes aged 18 to 50 years with a&#xD;
      confirmed diagnosis of anogenital warts.&#xD;
&#xD;
      In the course of the study, Ingaron was administered at a dose of 100,000 IU once a day every&#xD;
      other day in the period of 10 days.&#xD;
&#xD;
      Patients were divided into 2 groups: study and control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2009</start_date>
  <completion_date type="Actual">July 15, 2010</completion_date>
  <primary_completion_date type="Actual">June 30, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of anogenital warts</measure>
    <time_frame>Day 11</time_frame>
    <description>Number of participants with recurrent anogenital warts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence of anogenital warts</measure>
    <time_frame>Day 40</time_frame>
    <description>Number of participants with recurrent anogenital warts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence of anogenital warts</measure>
    <time_frame>Day 100</time_frame>
    <description>Number of participants with recurrent anogenital warts</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Human Papillomavirus Infection</condition>
  <condition>Anogenital Warts</condition>
  <arm_group>
    <arm_group_label>Interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a cryodestruction session, therapy with Ingaron 100,000 IU once a day every other day. The course of treatment consisted of 5 injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Cryodestruction session only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon gamma human recombinant (IFN-G)</intervention_name>
    <description>received by microbiological synthesis; specific antiviral activity on cells is 2x10*7 Units per mg of protein</description>
    <arm_group_label>Interferon</arm_group_label>
    <other_name>Ingaron</other_name>
    <other_name>Interferon gamma human recombinant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both sexes aged 18 to 50 years with a diagnosis of &quot;Anogenital warts&quot;.&#xD;
&#xD;
          2. The diagnosis &quot;Anogenital warts&quot; was made for the first time at least one year before&#xD;
             inclusion in the study.&#xD;
&#xD;
          3. During the last year prior to inclusion in the study, the patient had at least 2&#xD;
             recurrences of anogenital warts.&#xD;
&#xD;
          4. The diagnosis is confirmed by the detection of HPV by polymerase chain reaction (PCR).&#xD;
&#xD;
          5. Negative pregnancy test in women.&#xD;
&#xD;
          6. Availability of written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive test results for syphilis, hepatitis (HbsAg, anti-HCV), HIV infection,&#xD;
             gonococcal infection, urogenital trichomoniasis, chlamydial infection, inflammatory&#xD;
             diseases of the urogenital system caused by genital mycoplasmas.&#xD;
&#xD;
          2. Unsystematic use of barrier methods of contraception.&#xD;
&#xD;
          3. Pregnancy and lactation.&#xD;
&#xD;
          4. Known allergic reactions to interferons and / or other significant allergic diseases.&#xD;
&#xD;
          5. Any immunotropic therapy within the last 6 weeks prior to enrollment in the study.&#xD;
&#xD;
          6. The need to take drugs prohibited during the study.&#xD;
&#xD;
          7. Condition after organ transplantation, constant intake of immunosuppressive drugs.&#xD;
&#xD;
          8. Severe pathology from the cardiovascular system (uncontrolled arterial hypertension,&#xD;
             unstable angina pectoris, congestive heart failure, cardiac arrhythmias), a history of&#xD;
             myocardial infarction or cerebrovascular accident within the last 6 months.&#xD;
&#xD;
          9. Severe pathology on the part of the liver (increased content of AST, ALT 2 times&#xD;
             higher than the upper limit of the norm, the content of total bilirubin&gt; 2 mg / dL),&#xD;
             kidney (content of creatinine&gt; 1.5 mg / dL); signs of hepatic and / or renal failure.&#xD;
&#xD;
         10. The presence of severe pathology on the part of the respiratory system,&#xD;
             gastrointestinal tract, hematopoietic system.&#xD;
&#xD;
         11. Other serious (acute or chronic) pathological conditions, including mental illness, as&#xD;
             well as abnormalities in laboratory parameters, which, in the opinion of the&#xD;
             investigator, may increase the risk associated with participation in the study or&#xD;
             affect the interpretation of efficacy and safety data obtained in this research.&#xD;
&#xD;
         12. Alcohol and / or drug dependence.&#xD;
&#xD;
         13. Participation in other clinical trials in the last three months prior to inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonid Apanansky, Master</last_name>
    <role>Study Director</role>
    <affiliation>SPP Pharmaclon Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State scientific center of a dermatovenereology and cosmetology</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interferon gamma</keyword>
  <keyword>IFN-g</keyword>
  <keyword>HPV</keyword>
  <keyword>Anogenital warts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

